Innoviva, Inc.
General ticker "INVA" information:
- Sector: Health Care
- Industry: Pharmaceuticals
- Capitalization: $1.2B (TTM average)
Innoviva, Inc. follows the US Stock Market performance with the rate: 22.2%.
Estimated limits based on current volatility of 1.5%: low 20.67$, high 21.24$
Factors to consider:
- Total employees count: 127 as of 2024
- Top business risk factors: Market competition, Dependency on GSK, Cybersecurity threats, Regulatory and compliance, Product development risks
- Price in estimated range
- Earnings for 9 months up through Q3 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [17.17$, 25.27$]
- 2025-12-31 to 2026-12-31 estimated range: [18.21$, 26.84$]
Financial Metrics affecting the INVA estimates:
- Positive: with PPE of 10.2 at the end of fiscal year the price was low
- Positive: Operating cash flow per share per price, % of 17.01 > 13.24
- Positive: Operating profit margin, % of 46.52 > 18.64
- Negative: negative Industry operating cash flow (median)
- Positive: 41.86 < Shareholder equity ratio, % of 53.12 <= 63.39
- Positive: Interest expense per share per price, % of 2.00 <= 3.41
- Negative: Return on assets ratio (scaled to [-100,100]) of 1.77 <= 1.87
- Positive: -14.38 < Investing cash flow per share per price, % of -5.75
- Negative: -0.15 < Industry inventory ratio change (median), % of 0
Short-term INVA quotes
Long-term INVA plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $331.34MM | $310.46MM | $358.71MM |
| Operating Expenses | $368.29MM | $196.58MM | $191.84MM |
| Operating Income | $-36.95MM | $113.89MM | $166.87MM |
| Non-Operating Income | $323.89MM | $80.21MM | $-129.48MM |
| Interest Expense | $15.79MM | $19.16MM | $22.21MM |
| R&D Expense | $41.43MM | $33.92MM | $13.65MM |
| Income(Loss) | $286.95MM | $194.10MM | $37.39MM |
| Taxes | $66.69MM | $14.38MM | $14.00MM |
| Profit(Loss)* | $213.92MM | $179.72MM | $23.39MM |
| Stockholders Equity | $565.79MM | $674.96MM | $691.16MM |
| Inventory | $55.90MM | $40.74MM | $33.73MM |
| Assets | $1,231.50MM | $1,243.51MM | $1,301.06MM |
| Operating Cash Flow | $201.73MM | $141.06MM | $188.69MM |
| Capital expenditure | $0.07MM | $0.41MM | $0.27MM |
| Investing Cash Flow | $-56.63MM | $-66.76MM | $-63.79MM |
| Financing Cash Flow | $-55.57MM | $-171.84MM | $-13.45MM |
| Earnings Per Share** | $3.07 | $2.75 | $0.37 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.